Revolution Medicines

RVMD

市值 US$381億

Revolution Medicines Inc. (NASDAQ:RVMD) has significant growth opportunities beyond pancreatic cancer, according to William Blair, which initiated coverage of the biotechnology company with an Outperform rating and a $226 price forecast.

A European Medicines Agency committee on ​Thursday recommended approval of ‌Revolution Medicines' Rasonque in the EU for adults with pancreatic ​cancer that has spread ​and worsened after at least ⁠one prior treatment.

Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and clinically meaningful improvements across all primary and key secondary endpoints, regardless of tumor RAS mutation status Positive CHMP opinion follows an expedited phased review of RASONQUE under the EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of RASONQUE (daraxonrasib) once-daily oral tablets as a monotherapy indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of RASONQUE (daraxonrasib), a RAS(ON) multi-selective inhibitor, and zoldonrasib, an investigational RAS(ON) G12D-selective inhibitor, as a first-line treatment in adult patients with metastatic RAS G12D pancreatic adenocarcinoma (PDAC).

Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.

Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors aimed at treating some of the most difficult cancers.

Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval. The company's new medicine might become the top-prescribed treatment in its indication.

During the quarter, we added 8 new positions and exited 6 positions, bringing the number of positions in the Fund to 43. We re-established positions in two previously owned managed care companies, UnitedHealth Group Incorporated and Elevance Health, Inc. We established a new position in Sartorius Stedim Biotech S.A., which supplies equipment and reagents to biopharmaceutical companies for the production of biologic drugs.

REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company's RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. RASONQUE was recently approved by the U.S. FDA for the treatment of adult patients with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during its latest fiscal year. Revolution Medicines is a clinical-stage oncology specialist focused on high-stakes breakthrough therapies for RAS-addicted cancers.